Skip to content

Study on the treatment regimen of recurrent pulmonary tuberculosis

Study on the treatment regimen of recurrent pulmonary tuberculosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017441
Enrollment
Unknown
Registered
2018-07-30
Start date
2008-01-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

experimental group 1 with Non-diabetic TB patients:2HL2 EZS/2HL2EZS3/4HL2E
experimental group 2 with Non-diabetic TB patients:2HL2 EZS/2HL2EZS3/8HL2E
experimental group 3 with Non-diabetic TB patients:6HEZLfx/6HELfx
6 L2EZLfx/6 EL2Lfx
control group with Non-diabetic TB patients:2HREZS/6HRE
control group with diabetic TB patients:2HREZS/6HRE
experimental group with diabetic TB patients:6HEZLfx/6HELfx

Sponsors

Beijing Chest Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Sign informed consent; 2. aged between 18 and 65 years; 3. first episode of TB re-treatment and have used second-line anti-TB drugs = 2 months; 4. pulmonary active tuberculosis,sputum smear positive for acid-fast bacilli (AFB) and culture positive for M. tuberculosis; 5. with normal liver and kidney function, as well as normal blood and urine test results; fasting blood glucose control in = 7 mmol/L and with no complications of diabetes for diabetic TB patients.

Exclusion criteria

Exclusion criteria: 1. with active extra-pulmonary tuberculosis(concomitant tuberculous pleurisy is not excluded); 2. Nontuberculous mycobacteria; 3. Allergy to any anti-tuberculosis drug; 4. MDR-TB or XDR-TB; 5. active hepatitis, silicosis, renal dysfunction (urine protein positive> = 1 +, etc.), moderate to severe anemia or hematological diseases, pulmonary heart disease, respiratory failure and heart failure patients, long-term alcohol abuse, Immune diseases, malignancies, metabolic diseases.

Design outcomes

Primary

MeasureTime frame
cure rate;treatment completion rate;failure rate;death rate;default rate;relapse rate;Lesions absorption;cavity;

Countries

China

Contacts

Public ContactGao Weiwei

Beijing Chest Hospital, Capital Medical University

gwwjys@sina.com+86 13520619966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026